To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-08, Vol.16 (8), p.e0256567-e0256567 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0256567 |
|---|---|
| container_issue | 8 |
| container_start_page | e0256567 |
| container_title | PloS one |
| container_volume | 16 |
| creator | de Haan, Freek Bolarinwa, Oladimeji Akeem Guissou, Rosemonde Tou, Fatoumata Tindana, Paulina Boon, Wouter P C Moors, Ellen H M Cheah, Phaik Yeong Dhorda, Mehul Dondorp, Arjen M Ouedraogo, Jean Bosco Mokuolu, Olugbenga A Amaratunga, Chanaki |
| description | Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs have the potential to benefit the larger community and future patients by mitigating the risk of drug resistance. This study explores the extent to which the antimalarial drug markets in African countries are ready for a transition to TACTs.
A qualitative study was conducted in Nigeria and Burkina Faso and comprised in-depth interviews (n = 68) and focus group discussions (n = 11) with key actor groups in the innovation system of antimalarial therapies.
Evidence of ACT failure in African countries and explicit support for TACTs by the World Health Organization (WHO) and international funders were perceived important determinants for the market prospects of TACTs in Nigeria and Burkina Faso. At the country level, slow regulatory and implementation procedures were identified as potential barriers towards rapid TACTs deployment. Integrating TACTs in public sector distribution channels was considered relatively straightforward. More challenges were expected for integrating TACTs in private sector distribution channels, which are characterized by patient demand and profit motives. Finally, several affordability and acceptability issues were raised for which ACTs were suggested as a benchmark.
The market prospects of TACTs in Nigeria and Burkina Faso will depend on the demonstration of the added value of TACTs over ACTs, their advocacy by the WHO, the inclusion of TACTs in financial and regulatory arrangements, and their alignment with current distribution and deployment practices. Further clinical, health-economic and feasibility studies are required to inform decision makers about the broader implications of a transition to TACTs in African counties. The recent reporting of artemisinin resistance and ACT failure in Africa might change important determinants of the market readiness for TACTs. |
| doi_str_mv | 10.1371/journal.pone.0256567 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2567968933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A673834682</galeid><doaj_id>oai_doaj_org_article_0b7960eec00543d4ad1eae88bff71480</doaj_id><sourcerecordid>A673834682</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-c208861bec19e12321c6bd91b9a6c08e935e405184e6291ea87eefc99b830c3a3</originalsourceid><addsrcrecordid>eNqNk89u1DAQxiMEoqXwBggsISE47GLHWce5gFYVfypVqgSFqzVxJrsuWXuxHaCvwFMz291WXdQDyiGx85tvPJ9niuKp4FMha_HmIozRwzBdB49TXs7UTNX3ikPRyHKiSi7v3_o-KB6ldMH5TGqlHhYHsqpUJRt9WPw5D-zXEjLD3xl9ZhCR5SUy8NmtYIDoYGAriN8xJ-Y8m_fRWfDMhtHn6DCxiNBdsj5EBixH8MllFzzLgVZuPZBUzLhyyXnnJy0k7Ch41ToPW26JEdYk9O5x8aCHIeGT3fuo-Prh_fnxp8np2ceT4_npxKqmzBNbcq2VaNGKBkUpS2FV2zWibUBZrrGRM6z4TOgKVdkIBF0j9rZpWi25lSCPiudb3fUQktnZmAw5WDdKN1IScbIlugAXZh3JiXhpAjhztRHiwlBRzg5oeEtBHNGSuZXsKugoI2rd9n0tKs1J6-0u29iusLNkcoRhT3T_j3dLswg_ja54PVObw7zaCcTwY8SUDZlpcRjAYxivzq3LSteVJvTFP-jd1e2oBVABzveB8tqNqJmrWmpZkSBR0zsoejq6TEs91zva3wt4vRdATKamWsCYkjn58vn_2bNv--zLW-wSYcjLFIZx0z1pH6y2oI0hpYj9jcmCm83IXLthNiNjdiNDYc9uX9BN0PWMyL-CdROf</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2567968933</pqid></control><display><type>article</type><title>To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>EZB Electronic Journals Library</source><creator>de Haan, Freek ; Bolarinwa, Oladimeji Akeem ; Guissou, Rosemonde ; Tou, Fatoumata ; Tindana, Paulina ; Boon, Wouter P C ; Moors, Ellen H M ; Cheah, Phaik Yeong ; Dhorda, Mehul ; Dondorp, Arjen M ; Ouedraogo, Jean Bosco ; Mokuolu, Olugbenga A ; Amaratunga, Chanaki</creator><contributor>Okell, Lucy C.</contributor><creatorcontrib>de Haan, Freek ; Bolarinwa, Oladimeji Akeem ; Guissou, Rosemonde ; Tou, Fatoumata ; Tindana, Paulina ; Boon, Wouter P C ; Moors, Ellen H M ; Cheah, Phaik Yeong ; Dhorda, Mehul ; Dondorp, Arjen M ; Ouedraogo, Jean Bosco ; Mokuolu, Olugbenga A ; Amaratunga, Chanaki ; Okell, Lucy C.</creatorcontrib><description>Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs have the potential to benefit the larger community and future patients by mitigating the risk of drug resistance. This study explores the extent to which the antimalarial drug markets in African countries are ready for a transition to TACTs.
A qualitative study was conducted in Nigeria and Burkina Faso and comprised in-depth interviews (n = 68) and focus group discussions (n = 11) with key actor groups in the innovation system of antimalarial therapies.
Evidence of ACT failure in African countries and explicit support for TACTs by the World Health Organization (WHO) and international funders were perceived important determinants for the market prospects of TACTs in Nigeria and Burkina Faso. At the country level, slow regulatory and implementation procedures were identified as potential barriers towards rapid TACTs deployment. Integrating TACTs in public sector distribution channels was considered relatively straightforward. More challenges were expected for integrating TACTs in private sector distribution channels, which are characterized by patient demand and profit motives. Finally, several affordability and acceptability issues were raised for which ACTs were suggested as a benchmark.
The market prospects of TACTs in Nigeria and Burkina Faso will depend on the demonstration of the added value of TACTs over ACTs, their advocacy by the WHO, the inclusion of TACTs in financial and regulatory arrangements, and their alignment with current distribution and deployment practices. Further clinical, health-economic and feasibility studies are required to inform decision makers about the broader implications of a transition to TACTs in African counties. The recent reporting of artemisinin resistance and ACT failure in Africa might change important determinants of the market readiness for TACTs.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0256567</identifier><identifier>PMID: 34464398</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Antimalarials - therapeutic use ; Artemisinin ; Artemisinins - therapeutic use ; Burkina Faso ; Channels ; Combination therapy ; Current distribution ; Data collection ; Drug Approval ; Drug resistance ; Drug Therapy, Combination ; Feasibility studies ; Focus Groups ; Health risks ; Health sciences ; Humans ; Innovations ; Interviews ; Malaria ; Malaria - drug therapy ; Marketing ; Medicine ; Medicine and Health Sciences ; Nigeria ; Patient Acceptance of Health Care ; Patients ; People and Places ; Practice Guidelines as Topic ; Prescription Drugs ; Prevention ; Private Sector ; Public Sector ; Qualitative research ; Risk reduction ; Social Control, Formal ; Social Sciences ; Sustainable development ; Vector-borne diseases</subject><ispartof>PloS one, 2021-08, Vol.16 (8), p.e0256567-e0256567</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 de Haan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 de Haan et al 2021 de Haan et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-c208861bec19e12321c6bd91b9a6c08e935e405184e6291ea87eefc99b830c3a3</citedby><cites>FETCH-LOGICAL-c692t-c208861bec19e12321c6bd91b9a6c08e935e405184e6291ea87eefc99b830c3a3</cites><orcidid>0000-0003-4436-0983 ; 0000-0003-0412-8733</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407563/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407563/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34464398$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Okell, Lucy C.</contributor><creatorcontrib>de Haan, Freek</creatorcontrib><creatorcontrib>Bolarinwa, Oladimeji Akeem</creatorcontrib><creatorcontrib>Guissou, Rosemonde</creatorcontrib><creatorcontrib>Tou, Fatoumata</creatorcontrib><creatorcontrib>Tindana, Paulina</creatorcontrib><creatorcontrib>Boon, Wouter P C</creatorcontrib><creatorcontrib>Moors, Ellen H M</creatorcontrib><creatorcontrib>Cheah, Phaik Yeong</creatorcontrib><creatorcontrib>Dhorda, Mehul</creatorcontrib><creatorcontrib>Dondorp, Arjen M</creatorcontrib><creatorcontrib>Ouedraogo, Jean Bosco</creatorcontrib><creatorcontrib>Mokuolu, Olugbenga A</creatorcontrib><creatorcontrib>Amaratunga, Chanaki</creatorcontrib><title>To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs have the potential to benefit the larger community and future patients by mitigating the risk of drug resistance. This study explores the extent to which the antimalarial drug markets in African countries are ready for a transition to TACTs.
A qualitative study was conducted in Nigeria and Burkina Faso and comprised in-depth interviews (n = 68) and focus group discussions (n = 11) with key actor groups in the innovation system of antimalarial therapies.
Evidence of ACT failure in African countries and explicit support for TACTs by the World Health Organization (WHO) and international funders were perceived important determinants for the market prospects of TACTs in Nigeria and Burkina Faso. At the country level, slow regulatory and implementation procedures were identified as potential barriers towards rapid TACTs deployment. Integrating TACTs in public sector distribution channels was considered relatively straightforward. More challenges were expected for integrating TACTs in private sector distribution channels, which are characterized by patient demand and profit motives. Finally, several affordability and acceptability issues were raised for which ACTs were suggested as a benchmark.
The market prospects of TACTs in Nigeria and Burkina Faso will depend on the demonstration of the added value of TACTs over ACTs, their advocacy by the WHO, the inclusion of TACTs in financial and regulatory arrangements, and their alignment with current distribution and deployment practices. Further clinical, health-economic and feasibility studies are required to inform decision makers about the broader implications of a transition to TACTs in African counties. The recent reporting of artemisinin resistance and ACT failure in Africa might change important determinants of the market readiness for TACTs.</description><subject>Antimalarials - therapeutic use</subject><subject>Artemisinin</subject><subject>Artemisinins - therapeutic use</subject><subject>Burkina Faso</subject><subject>Channels</subject><subject>Combination therapy</subject><subject>Current distribution</subject><subject>Data collection</subject><subject>Drug Approval</subject><subject>Drug resistance</subject><subject>Drug Therapy, Combination</subject><subject>Feasibility studies</subject><subject>Focus Groups</subject><subject>Health risks</subject><subject>Health sciences</subject><subject>Humans</subject><subject>Innovations</subject><subject>Interviews</subject><subject>Malaria</subject><subject>Malaria - drug therapy</subject><subject>Marketing</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Nigeria</subject><subject>Patient Acceptance of Health Care</subject><subject>Patients</subject><subject>People and Places</subject><subject>Practice Guidelines as Topic</subject><subject>Prescription Drugs</subject><subject>Prevention</subject><subject>Private Sector</subject><subject>Public Sector</subject><subject>Qualitative research</subject><subject>Risk reduction</subject><subject>Social Control, Formal</subject><subject>Social Sciences</subject><subject>Sustainable development</subject><subject>Vector-borne diseases</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk89u1DAQxiMEoqXwBggsISE47GLHWce5gFYVfypVqgSFqzVxJrsuWXuxHaCvwFMz291WXdQDyiGx85tvPJ9niuKp4FMha_HmIozRwzBdB49TXs7UTNX3ikPRyHKiSi7v3_o-KB6ldMH5TGqlHhYHsqpUJRt9WPw5D-zXEjLD3xl9ZhCR5SUy8NmtYIDoYGAriN8xJ-Y8m_fRWfDMhtHn6DCxiNBdsj5EBixH8MllFzzLgVZuPZBUzLhyyXnnJy0k7Ch41ToPW26JEdYk9O5x8aCHIeGT3fuo-Prh_fnxp8np2ceT4_npxKqmzBNbcq2VaNGKBkUpS2FV2zWibUBZrrGRM6z4TOgKVdkIBF0j9rZpWi25lSCPiudb3fUQktnZmAw5WDdKN1IScbIlugAXZh3JiXhpAjhztRHiwlBRzg5oeEtBHNGSuZXsKugoI2rd9n0tKs1J6-0u29iusLNkcoRhT3T_j3dLswg_ja54PVObw7zaCcTwY8SUDZlpcRjAYxivzq3LSteVJvTFP-jd1e2oBVABzveB8tqNqJmrWmpZkSBR0zsoejq6TEs91zva3wt4vRdATKamWsCYkjn58vn_2bNv--zLW-wSYcjLFIZx0z1pH6y2oI0hpYj9jcmCm83IXLthNiNjdiNDYc9uX9BN0PWMyL-CdROf</recordid><startdate>20210831</startdate><enddate>20210831</enddate><creator>de Haan, Freek</creator><creator>Bolarinwa, Oladimeji Akeem</creator><creator>Guissou, Rosemonde</creator><creator>Tou, Fatoumata</creator><creator>Tindana, Paulina</creator><creator>Boon, Wouter P C</creator><creator>Moors, Ellen H M</creator><creator>Cheah, Phaik Yeong</creator><creator>Dhorda, Mehul</creator><creator>Dondorp, Arjen M</creator><creator>Ouedraogo, Jean Bosco</creator><creator>Mokuolu, Olugbenga A</creator><creator>Amaratunga, Chanaki</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4436-0983</orcidid><orcidid>https://orcid.org/0000-0003-0412-8733</orcidid></search><sort><creationdate>20210831</creationdate><title>To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?</title><author>de Haan, Freek ; Bolarinwa, Oladimeji Akeem ; Guissou, Rosemonde ; Tou, Fatoumata ; Tindana, Paulina ; Boon, Wouter P C ; Moors, Ellen H M ; Cheah, Phaik Yeong ; Dhorda, Mehul ; Dondorp, Arjen M ; Ouedraogo, Jean Bosco ; Mokuolu, Olugbenga A ; Amaratunga, Chanaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-c208861bec19e12321c6bd91b9a6c08e935e405184e6291ea87eefc99b830c3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antimalarials - therapeutic use</topic><topic>Artemisinin</topic><topic>Artemisinins - therapeutic use</topic><topic>Burkina Faso</topic><topic>Channels</topic><topic>Combination therapy</topic><topic>Current distribution</topic><topic>Data collection</topic><topic>Drug Approval</topic><topic>Drug resistance</topic><topic>Drug Therapy, Combination</topic><topic>Feasibility studies</topic><topic>Focus Groups</topic><topic>Health risks</topic><topic>Health sciences</topic><topic>Humans</topic><topic>Innovations</topic><topic>Interviews</topic><topic>Malaria</topic><topic>Malaria - drug therapy</topic><topic>Marketing</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Nigeria</topic><topic>Patient Acceptance of Health Care</topic><topic>Patients</topic><topic>People and Places</topic><topic>Practice Guidelines as Topic</topic><topic>Prescription Drugs</topic><topic>Prevention</topic><topic>Private Sector</topic><topic>Public Sector</topic><topic>Qualitative research</topic><topic>Risk reduction</topic><topic>Social Control, Formal</topic><topic>Social Sciences</topic><topic>Sustainable development</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Haan, Freek</creatorcontrib><creatorcontrib>Bolarinwa, Oladimeji Akeem</creatorcontrib><creatorcontrib>Guissou, Rosemonde</creatorcontrib><creatorcontrib>Tou, Fatoumata</creatorcontrib><creatorcontrib>Tindana, Paulina</creatorcontrib><creatorcontrib>Boon, Wouter P C</creatorcontrib><creatorcontrib>Moors, Ellen H M</creatorcontrib><creatorcontrib>Cheah, Phaik Yeong</creatorcontrib><creatorcontrib>Dhorda, Mehul</creatorcontrib><creatorcontrib>Dondorp, Arjen M</creatorcontrib><creatorcontrib>Ouedraogo, Jean Bosco</creatorcontrib><creatorcontrib>Mokuolu, Olugbenga A</creatorcontrib><creatorcontrib>Amaratunga, Chanaki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Science in Context</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Database (1962 - current)</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Haan, Freek</au><au>Bolarinwa, Oladimeji Akeem</au><au>Guissou, Rosemonde</au><au>Tou, Fatoumata</au><au>Tindana, Paulina</au><au>Boon, Wouter P C</au><au>Moors, Ellen H M</au><au>Cheah, Phaik Yeong</au><au>Dhorda, Mehul</au><au>Dondorp, Arjen M</au><au>Ouedraogo, Jean Bosco</au><au>Mokuolu, Olugbenga A</au><au>Amaratunga, Chanaki</au><au>Okell, Lucy C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-08-31</date><risdate>2021</risdate><volume>16</volume><issue>8</issue><spage>e0256567</spage><epage>e0256567</epage><pages>e0256567-e0256567</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (ACTs) are still effective, TACTs have the potential to benefit the larger community and future patients by mitigating the risk of drug resistance. This study explores the extent to which the antimalarial drug markets in African countries are ready for a transition to TACTs.
A qualitative study was conducted in Nigeria and Burkina Faso and comprised in-depth interviews (n = 68) and focus group discussions (n = 11) with key actor groups in the innovation system of antimalarial therapies.
Evidence of ACT failure in African countries and explicit support for TACTs by the World Health Organization (WHO) and international funders were perceived important determinants for the market prospects of TACTs in Nigeria and Burkina Faso. At the country level, slow regulatory and implementation procedures were identified as potential barriers towards rapid TACTs deployment. Integrating TACTs in public sector distribution channels was considered relatively straightforward. More challenges were expected for integrating TACTs in private sector distribution channels, which are characterized by patient demand and profit motives. Finally, several affordability and acceptability issues were raised for which ACTs were suggested as a benchmark.
The market prospects of TACTs in Nigeria and Burkina Faso will depend on the demonstration of the added value of TACTs over ACTs, their advocacy by the WHO, the inclusion of TACTs in financial and regulatory arrangements, and their alignment with current distribution and deployment practices. Further clinical, health-economic and feasibility studies are required to inform decision makers about the broader implications of a transition to TACTs in African counties. The recent reporting of artemisinin resistance and ACT failure in Africa might change important determinants of the market readiness for TACTs.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34464398</pmid><doi>10.1371/journal.pone.0256567</doi><tpages>e0256567</tpages><orcidid>https://orcid.org/0000-0003-4436-0983</orcidid><orcidid>https://orcid.org/0000-0003-0412-8733</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-08, Vol.16 (8), p.e0256567-e0256567 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2567968933 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; Free Full-Text Journals in Chemistry; EZB Electronic Journals Library |
| subjects | Antimalarials - therapeutic use Artemisinin Artemisinins - therapeutic use Burkina Faso Channels Combination therapy Current distribution Data collection Drug Approval Drug resistance Drug Therapy, Combination Feasibility studies Focus Groups Health risks Health sciences Humans Innovations Interviews Malaria Malaria - drug therapy Marketing Medicine Medicine and Health Sciences Nigeria Patient Acceptance of Health Care Patients People and Places Practice Guidelines as Topic Prescription Drugs Prevention Private Sector Public Sector Qualitative research Risk reduction Social Control, Formal Social Sciences Sustainable development Vector-borne diseases |
| title | To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T15%3A37%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=To%20what%20extent%20are%20the%20antimalarial%20markets%20in%20African%20countries%20ready%20for%20a%20transition%20to%20triple%20artemisinin-based%20combination%20therapies?&rft.jtitle=PloS%20one&rft.au=de%20Haan,%20Freek&rft.date=2021-08-31&rft.volume=16&rft.issue=8&rft.spage=e0256567&rft.epage=e0256567&rft.pages=e0256567-e0256567&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0256567&rft_dat=%3Cgale_plos_%3EA673834682%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2567968933&rft_id=info:pmid/34464398&rft_galeid=A673834682&rft_doaj_id=oai_doaj_org_article_0b7960eec00543d4ad1eae88bff71480&rfr_iscdi=true |